Meet Our Team
Accomplished. Experienced.
Leadership Team
-
Eric B. Kmiec, Ph.D.
Founder & Chief Executive Officer
-
Jan Case
Chief Operating Officer
-
Jon Brilliant
Chief Financial Officer
-
Michael Alexander, Ph.D.
General Counsel
Our team is complemented by a seasoned network of focused advisors and consultants. This flexible, expert-driven model allows us to supplement core internal skillsets with highly specialized capabilities as needed.
-
Panos Argiras
CMC Consultant
-
Jill Conwell
Organization & Project Management
-
Michael Miller, Ph.D.
Regulatory Affairs
-
Natalia Rivera-Torres, Ph.D.
Research & Development
-
Jenny Zilberberg, Ph.D.
Translational Immunology
Board of Directors
-
Janice E. Nevin, M.D.
Board Chair
President & CEO, ChristianaCare -
Jeffrey Carper
Entrepreneur and Investor
Co-Founder, Gentas Biotechnology -
Jill Castilla
Chair, President & CEO
Citizens Bank of Edmond -
Eric B. Kmiec, Ph.D.
Founder & CEO
CorriXR Therapeutics, Inc.
Clinical & Scientific Advisory Boards
-
Bhisham Chera, M.D., FASTRO
Endowed Chair in Radiation Oncology
Hollings Cancer Center
Medical University of South Carolina -
Robert L. Ferris, M.D., Ph.D.
Executive Director,
Lineberger Comprehensive Cancer Center
University of North Carolina -
Glenn J. Hanna, M.D.
Director, Center for Cancer Therapeutic Innovation
Dana-Farber Cancer Institute
Harvard Medical School -
Neil Hockstein, M.D.
Director of Head and Neck Multidisciplinary Care,
Helen F. Graham Cancer Center & Research Institute
ChristianaCare -
Mark Behlke, M.D., Ph.D.
Chief Scientific Officer
IDT -
Zhi Chen, Ph.D.
Co-Founder & CEO
Gentas Biotechnology -
Nicholas J. Petrelli, M.D., FACS
Director, Cawley Center for Translational Cancer Research
Helen F. Graham Cancer Center & Research Institute, ChristianaCare -
Gregory J. Tiesi, M.D.
Chief of Surgical Oncology: Southern Region
Medical Director of Hepatobiliary Surgery, Hackensack Meridian Jersey Shore University Medical Center
ChristianaCare Gene Editing Institute
CorriXR is the inaugural biotech spin-out of ChristianaCare, a large healthcare system, and the Gene Editing Institute, which has been embedded in ChristianaCare’s Helen F. Graham Cancer Center & Research Institute since 2015. This unique collaboration provides direct access to oncologists, researchers and patient populations — de-risking clinical translation and speeding time to market.
The Gene Editing Institute is CorriXR’s unmatched research and development engine. These scientists bring decades of gene editing research and technology development experience and support including:
PDX and PDC mouse model validation
Critical in vivo studies
Cell model development and refinement
Next Generation Sequencing (NGS) capabilities and advanced analytics
Our Research
Learn more about our recent scientific publications